RIPA-56是一种高效力、代谢稳定的选择性RIP1 (RIPK1)抑制剂。 应用： RIPA-56 是一种高效选择和代谢稳定的受体相互作用蛋白 1 (RIP1) 抑制剂，IC50 为 13 nM。RIPA-56 可用于研究全身炎症反应综合征。 Information RIPA-56 RIPA-56 is a highly-potent, selective, and metabolically stable RIP1 (RIPK1) inhibitor. Targets RIP1 (Cell-free) 13 nM In vitro RIPA-56 shows efficient inhibition of RIP1 kinase activity, with an IC50 of 13 nM. It showed no inhibition of RIP3 kinase activity at a 10 µM concentration. RIPA-56 does not inhibit IDO activity at a concentration of 200 µM, which represents an estimated 10,000-fold selectivity window based on the RIP1 ADP-Glo activity of 13 nM. In vivo RIPA-56 has an impressive PK profile in mice, with a 3.1 h half-life, 22% oral bioavailability (PO), and 100% bioavailability from intraperitoneal injection (IP). RIPA-56 has great ability in transporting across blood brain barrier. In the SIRS mice disease model, RIPA-56 efficiently reduced tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage.